Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension

American Journal of Ophthalmology

Volumn 149, Issue 4, 2010, Pages

  Katz, L Jay ^a   Cohen, John S ^b   Batoosingh, Amy L ^c   Felix, Carlos ^c   Shu, Vincent ^c   Schiffman, Rhett M ^c  

^a WILLS EYE HOSPITAL   (United States)

^b CINCINNATI EYE INSTITUTE   (United States)

^c ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST;

ABNORMAL SENSATION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE IRRITATION; EYELASH GROWTH; EYELID ERYTHEMA; FEMALE; FOREIGN BODY SENSATION; GLAUCOMA; HAIR GROWTH; HUMAN; HYPERPIGMENTATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA CYSTOID EDEMA; RISK BENEFIT ANALYSIS; SIDE EFFECT; UVEITIS;

EID: 77949626844     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.12.003     Document Type: Article

References (30)

1. Woodward D.F., Phelps R.L., Krauss A.H., et al. Bimatoprost: a novel antiglaucoma agent. Cardiovasc Drug Rev 22 (2004) 103-120
2. Higginbotham E.J., Schuman J.S., Goldberg I., et al. Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 120 (2002) 1286-1293
3. Cohen J.S., Gross R.L., Cheetham J.K., VanDenburgh A.M., Bernstein P., and Whitcup S.M. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 49 Suppl 1 (2004) S45-S52
4. Williams R.D., Cohen J.S., Gross R.L., Liu C.C., Safyan E., Batoosingh A.L., and Bimatoprost Study Group. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol 92 (2008) 1387-1392
5. Aptel F., Cucherat M., and Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 17 (2008) 667-673
6. Noecker R.S., Dirks M.S., Choplin N.T., Bernstein P., Batoosingh A.L., Whitcup S.M., and Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135 (2003) 55-63
7. Simmons S.T., Dirks M.S., and Noecker R.J. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther 21 (2004) 247-262
8. van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P., Hendrikse F., and Prins M.H. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112 (2005) 1177-1185
9. Holmstrom S., Buchholz P., Walt J., Wickstrom J., and Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 21 (2005) 1875-1883
10. Cantor L.B., Hoop J., Morgan L., Wudunn D., Catoira Y., and Bimatoprost-Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 90 (2006) 1370-1373
11. Denis P., Lafuma A., Khoshnood B., Mimaud V., and Berdeaux G. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 23 (2007) 601-608
12. Wanichwecha-Rungruang B., and Iemsomboon W. Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand. J Med Assoc Thai 88 (2005) 1228-1235
13. Hommer A., and Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 17 (2007) 53-62
14. Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 6 (2007) 45-52
15. Nakamura T., Yamada M., Teshima M., et al. Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull 30 (2007) 2360-2364
16. Toor A., Chanis R.A., Polikoff L.A., Fahim M.M., Sinha A.P., and Serle J.B. Additivity of pilocarpine to bimatoprost in ocular hypertension and early glaucoma. J Glaucoma 14 (2005) 243-248
17. Le Henanff A., Giraudeau B., Baron G., and Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA 295 (2006) 1147-1151
18. Schwartz G.F., and Reardon G. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol 49 (2004) 621-623 author reply 623-624
19. Pisella P.J., Debbasch C., Hamard P., et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 45 (2004) 1360-1368
20. Guenoun J.M., Baudouin C., Rat P., Pauly A., Warnet J.M., and Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 46 (2005) 2444-2450
21. Whitson J.T., Cavanagh H.D., Lakshman N., and Petroll W.M. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 23 (2006) 663-671
22. Liang H., Baudouin C., Pauly A., and Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 92 (2008) 1275-1282
23. Kahook M.Y., and Noecker R.J. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 27 (2008) 339-343
24. Hamacher T., Airaksinen J., Saarela V., Liinamaa M.J., Richter U., and Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf) 242 (2008) 14-19
25. Gross R.L., Peace J.H., Smith S.E., et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 17 (2008) 217-222
26. Lewis R.A., Katz G.J., Weiss M.J., et al., Travoprost BAC-free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 16 (2007) 98-103
27. Camras C.B., Alm A., Watson P., Stjernschantz J., and Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 103 (1996) 1916-1924
28. Goldberg I., Li X.Y., Selaru P., and Paggiarino D. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 18 (2008) 408-416
29. Brandt J.D., Beiser J.A., Gordon M.O., Kass M.A., and Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol 138 (2004) 717-722
30. Harasymowycz P.J., Papamatheakis D.G., Ennis M., Brady M., Gordon K.D., and Travoprost Central Corneal Thickness Study Group. Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma. Cornea 26 (2007) 34-41